DexCom Statistics
Total Valuation
DexCom has a market cap or net worth of $28.74 billion. The enterprise value is $28.76 billion.
| Market Cap | 28.74B |
| Enterprise Value | 28.76B |
Important Dates
The next estimated earnings date is Thursday, April 24, 2025, after market close.
| Earnings Date | Apr 24, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
DexCom has 390.77 million shares outstanding. The number of shares has decreased by -3.01% in one year.
| Current Share Class | 390.77M |
| Shares Outstanding | 390.77M |
| Shares Change (YoY) | -3.01% |
| Shares Change (QoQ) | -0.85% |
| Owned by Insiders (%) | 0.35% |
| Owned by Institutions (%) | 93.44% |
| Float | 387.84M |
Valuation Ratios
The trailing PE ratio is 51.65 and the forward PE ratio is 36.46. DexCom's PEG ratio is 1.55.
| PE Ratio | 51.65 |
| Forward PE | 36.46 |
| PS Ratio | 7.18 |
| Forward PS | 6.12 |
| PB Ratio | 13.67 |
| P/TBV Ratio | 14.54 |
| P/FCF Ratio | 45.57 |
| P/OCF Ratio | 29.05 |
| PEG Ratio | 1.55 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 35.17, with an EV/FCF ratio of 45.59.
| EV / Earnings | 49.91 |
| EV / Sales | 7.13 |
| EV / EBITDA | 35.17 |
| EV / EBIT | 47.93 |
| EV / FCF | 45.59 |
Financial Position
The company has a current ratio of 1.47, with a Debt / Equity ratio of 1.23.
| Current Ratio | 1.47 |
| Quick Ratio | 1.23 |
| Debt / Equity | 1.23 |
| Debt / EBITDA | 3.04 |
| Debt / FCF | 4.11 |
| Interest Coverage | 31.58 |
Financial Efficiency
Return on equity (ROE) is 27.63% and return on invested capital (ROIC) is 8.01%.
| Return on Equity (ROE) | 27.63% |
| Return on Assets (ROA) | 5.88% |
| Return on Invested Capital (ROIC) | 8.01% |
| Return on Capital Employed (ROCE) | 16.89% |
| Revenue Per Employee | $391,553 |
| Profits Per Employee | $55,942 |
| Employee Count | 10,300 |
| Asset Turnover | 0.63 |
| Inventory Turnover | 2.79 |
Taxes
In the past 12 months, DexCom has paid $132.80 million in taxes.
| Income Tax | 132.80M |
| Effective Tax Rate | 18.73% |
Stock Price Statistics
The stock price has decreased by -44.80% in the last 52 weeks. The beta is 1.29, so DexCom's price volatility has been higher than the market average.
| Beta (5Y) | 1.29 |
| 52-Week Price Change | -44.80% |
| 50-Day Moving Average | 82.84 |
| 200-Day Moving Average | 82.26 |
| Relative Strength Index (RSI) | 40.55 |
| Average Volume (20 Days) | 4,301,326 |
Short Selling Information
The latest short interest is 9.48 million, so 2.43% of the outstanding shares have been sold short.
| Short Interest | 9.48M |
| Short Previous Month | 9.85M |
| Short % of Shares Out | 2.43% |
| Short % of Float | 2.44% |
| Short Ratio (days to cover) | 2.82 |
Income Statement
In the last 12 months, DexCom had revenue of $4.03 billion and earned $576.20 million in profits. Earnings per share was $1.42.
| Revenue | 4.03B |
| Gross Profit | 2.44B |
| Operating Income | 600.00M |
| Pretax Income | 806.90M |
| Net Income | 576.20M |
| EBITDA | 817.70M |
| EBIT | 600.00M |
| Earnings Per Share (EPS) | $1.42 |
Balance Sheet
The company has $2.58 billion in cash and $2.59 billion in debt, giving a net cash position of -$14.40 million or -$0.04 per share.
| Cash & Cash Equivalents | 2.58B |
| Total Debt | 2.59B |
| Net Cash | -14.40M |
| Net Cash Per Share | -$0.04 |
| Equity (Book Value) | 2.10B |
| Book Value Per Share | 5.38 |
| Working Capital | 1.37B |
Cash Flow
In the last 12 months, operating cash flow was $989.50 million and capital expenditures -$358.80 million, giving a free cash flow of $630.70 million.
| Operating Cash Flow | 989.50M |
| Capital Expenditures | -358.80M |
| Free Cash Flow | 630.70M |
| FCF Per Share | $1.61 |
Margins
Gross margin is 60.46%, with operating and profit margins of 14.88% and 14.29%.
| Gross Margin | 60.46% |
| Operating Margin | 14.88% |
| Pretax Margin | 17.58% |
| Profit Margin | 14.29% |
| EBITDA Margin | 20.28% |
| EBIT Margin | 14.88% |
| FCF Margin | 15.64% |
Dividends & Yields
DexCom does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | 3.01% |
| Shareholder Yield | 3.01% |
| Earnings Yield | 2.00% |
| FCF Yield | 2.19% |
Analyst Forecast
The average price target for DexCom is $99.82, which is 35.77% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $99.82 |
| Price Target Difference | 35.77% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 17 |
| Revenue Growth Forecast (5Y) | 15.13% |
| EPS Growth Forecast (5Y) | 23.49% |
Stock Splits
The last stock split was on June 13, 2022. It was a forward split with a ratio of 4:1.
| Last Split Date | Jun 13, 2022 |
| Split Type | Forward |
| Split Ratio | 4:1 |
Scores
DexCom has an Altman Z-Score of 6.99 and a Piotroski F-Score of 6.
| Altman Z-Score | 6.99 |
| Piotroski F-Score | 6 |